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Cold urticaria is one of the least common types of 
urticaria, affecting approximately 1% to 3% of all patients 
with urticaria [1]. Patients present generalized or local wheal 
lesions in areas that come into contact with cold stimuli such 
as cold air, water, or objects. The symptoms may or may not 
be accompanied by angioedema. Cold urticaria can be primary 
or associated with other pathologies such as cryoglobulinemia, 
infections, leukocytoclastic vasculitis, or neoplasia.
The greatest risk with this kind of urticaria is the 
development of a systemic reaction resulting in hemodynamic 
collapse during generalized cold exposure (eg, swimming in 
the sea or a swimming pool).
We report the case of an 82-year-old man with a 
background of allergy to penicillin. The patient had been 
scheduled for aortic endoprosthesis implantation to treat an 
aortic aneurysm. On the day of surgery, he was premedicated 
with 2 mg of midazolam in a saline solution with no additives. 
Some minutes later, he was transferred to the operating room 
and the saline solution was infused again. He immediately 
presented erythema and itching in the perfusion area on the left 
arm, following the outline of the veins. The peripheral catheter 
was consequently removed and placed in the right arm, but the 
same reaction appeared after infusion of the saline solution. 
The nurse had used sterile latex gloves to place the catheter.
Methylprednisolone 125 mg and a vial of dexchlor-
pheniramine were administered, and the symptoms yielded. 
Nevertheless, when the saline solution was infused again, the 
symptoms returned, and surgery was stopped.
In the allergy study, skin tests to latex, which was 
considered a possible triggering factor, were negative, as were 
prick and intradermal tests to midazolam. An ice cube test was 
performed by placing an ice cube covered with parafi lm on 
the patient’s forearm for 10 minutes, with readings taken at 
5 and 20 minutes. A positive wheal of 35x30 mm exceeding 
the limits of the ice cube was observed after 20 minutes. At 
this time, the patient reported having experienced on other 
occasions symptoms of acute urticaria after contact with cold 
water, with no other symptoms
Surgery was rescheduled for the next day. The temperature 
in the operating room was increased and the sera were 
heated. Corticosteroid and antihistamine premedication was 
administered, and the operation was performed without 
complications. The administration of midazolam was avoided. 
Allergic reactions to the drugs used in anesthesia are a 
frequent cause of morbidity in the operating room. We report 
the case of a patient who experienced a skin reaction before 
the administration of anesthetics. Once latex allergy had been 
ruled out as a possible trigger, the patient was questioned again 
about his history, and he reported reactions compatible with 
cold urticaria. This is a rare form of allergy in the operating 
room, where the temperature is usually 19ºC to 21ºC [2], 
but patients can sometimes present hypothermia symptoms 
before the beginning of surgery. Data about the temperature of 
solutions administered to patients are not available, but solutions 
administered during surgery are usually cold, since in most cases 
they are at the same temperature as the room and are not heated 
before being infused into the patient. Consequently, they can 
cause reactions such as that experienced by our patient.
Avoidance of exposure to cold is the most important 
prevention measure and in patients in whom symptoms are 
frequent, the administration of antihistamines is common [3]. 
For patients with an insuffi cient response to antihistamines, 
antileukotrienes [4] or even an anti-immunoglobulin 
E monoclonal antibody (omalizumab) [5] should be 
considered.
 
References
  1. Buss YL, Sticherling M. Cold urticaria; disease course and 
outcome—an investigation of 85 patients before and after 
therapy. Br J Dermatol. 2005. 153(2): 440-1.
  2. Wang CS, Chen CL, Huang CJ, Cheng KW, Chen KH, Wang CC, 
Concejero AM, Cheng YF, Huang TL, Wang SH, Lin CC, Liu YW, 
Yong CC, Yang CH, Jawan B. Effects of different operating room 
temperatures on the body temperature undergoing live liver 
donor hepatectomy. Transplant Proc. 2008. 40(8): 2463-5.
  3.  Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Vieira 
dos Santos R, Maurer M, Zuberbier T. Acquired cold urticaria: 
clinical picture and update on diagnosis and treatment. Clin 
Exp Dermatology, 32, 241-5.
  4. Bonadonna P, Lombardi C, Senna G, Canonica GW, Passalacqua 
G. Treatment of acquired cold urticaria with cetirizine and 
zafi rlukast in combination. J Am Acad Dermatol. 2003. 49(4): 
714-6.
  5. Boyce JA. Successful treatment of cold-induced urticaria/
anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006. 117(6): 
1415-8.
J Investig Allergol Clin Immunol 2010; Vol. 20(5): 446-453 © 2010 Esmon Publicidad
Practitioner’s Corner447
Table. Desensitization Protocol for Interferon α-2aa
  
 Day Dilution Amount, mL Drug dose, MIUb   
 1 1 MIU/mL
  1/1 000 000 0.5 0.5
  1/100 000 0.5 5
  1/10 000 0.5 50
  1/1000 0.5 500
  1/100 0.5 5000
  1/10 0.5 50 000
  1/1 0.1 100 000
                                       Total dose=0.155 MIU 
 2 1 MIU/mL 0.1 100 000
  2 MIU/mL 0.1 200 000
   0.2 400 000
   0.4 800 000
   0.5 1 000 000
                                          Total dose=2.5 MIU
 3 4.5 MIU/0.5mL
   0.1 900 000
   0.2 1 800 000
                                          Total dose=2.7 MIU
 4 4.5 MIU/0.5mL 0.44 4 000 000
                                            Total dose=4 MIU
Abbreviations: MIU, million international units.
aPatient’s weight: 16 kg (0.67 m2).
bInjections were administered subcutaneously at 30-minute intervals.
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Interferon (IFN) α is used worldwide for the treatment of 
chronic hepatitis B (CHB) infection, and acute adverse effects 
during treatment are very common [1,2]. Dermatological effects 
include urticaria and angioedema. It has been demonstrated that 
the allergic reactions that appear during treatment can involve 
both immunoglobulin (Ig) E-mediated and non-IgE-mediated 
mechanisms [3,4]. We present a case where desensitization was 
successfully performed with IFN α-2a in a child with CHB. 
A 3-year-old boy diagnosed with CHB was initiated on 
IFN α-2a treatment and developed angioedema and urticaria 
10 hours after receiving the second dose. He was not on any 
other mediation at the time. The treatment was discontinued 
and the lesions disappeared within 18 to 20 hours. INF α-2a 
treatment was re-administered using the same dosage 2 days 
later and the same lesions reappeared. The treatment was 
interrupted again, this time for a 2-week period, after which 
it was decided to start treatment with IFN α-2b. However, the 
patient developed angioedema and urticaria 10 to 12 hours after 
the fi rst dose, leading to a suspicion of allergy to IFN-α. The 
drug was immediately stopped and the lesions disappeared 
without relapse in 12 to 18 hours. The patient underwent a 
skin prick test followed by an intradermal test with IFN α-2a 
and IFN α-2b, with no late or early reactions observed in any 
of the tests. The desensitization protocol shown in the Table 
was carried out with IFN α-2a. No reactions were observed 
on the fi rst day. On the second day, the patient developed 
angioedema and urticaria 8 to 10 hours after administration 
of the 0.5 mL injection with 2 MIU/mL solution. The patient 
was given a single dose of antihistamine and the lesions 
disappeared without relapse 8 to 10 hours later. On the 
third day of desensitization, 0.2 mL of 2 MIU/mL dilution 
was administered to the patient by going 2 steps back from 
the previous dose. Except for the reaction that developed 
on the second day, no other reactions were observed and 
the desensitization protocol was successfully completed. 
Subsequently, IFN α treatment was maintained continuously 
with 6 MIU/m2/dose 3 days a week. No further reactions were 
observed during a 100-day follow-up period.
Desensitization is a process that aims to remove IgE-
induced sensitivity to a particular drug when there is no 
alternative treatment. Although the term desensitization is 
generally limited to IgE-mediated reactions, it also describes 
the nonresponsive condition that occurs as a result of repeated 
and ever-increasing encounters with a drug. It can also include 
delayed-type, non-IgE-mediated reactions [5,6]. There are a 
limited number of studies reporting the successful application 
of desensitization in adults with IFN allergy. Kalpaklioglu 
et al [7] successfully implemented a desensitization process 
with IFN ß-1a in a 41-year-old patient, as did Taghavi et al [8] 
with IFN α-2b in a 65-year-old patient. The skin tests for IFN 
were positive in both cases. Ours is the fi rst case in the literature 
that describes the successful application of a desensitization 
protocol with IFN α-2a in childhood. No early or late reactions 
with either IFN α-2a or IFN α-2b were detected in either the 
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skin prick or intradermal tests in our patient. Although skin 
tests performed with IFN α have not yet been completely 
standardized, we considered a non-IgE mediated reaction 
against IFN α in our patient. The young age of the patient may 
partly explain the negative skin test with IFN α. However, it has 
been reported that desensitization can be successfully applied 
in non-IgE mediated drug reactions [9]. 
In the present study, we successfully applied a desensitization 
protocol with IFN α-2a in a child. We believe that IFN α 
desensitization should be considered in diseases in which there 
is no alternative treatment. 
References
  1. Yeung LT, Roberts EA, Current issues in the management of 
paediatric viral hepatitis. Liver Int. 2009 Oct 19. [Epub ahead of 
print].
  2. Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan 
JM, Johnson JR, Tacklind J, Rutks I, Kane RL. Management of 
chronic hepatitis B. Evid Rep Technol Assess. 2008; 174:1-671.
  3.  Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, 
Smelko B, Donnelly S, Stover L. Mechanisms and management 
of toxicities associated with high-dose interferon alfa-2b 
therapy. J Clin Oncol, 2002; 20:3703-18.
  4.  Beckman DB, Mathisen TL, Harris KE, Boxer MB, Grammer LC. 
Hypersensitivity to IFN-alpha. Allergy. 2001; 56 :806-7.
  5.  Solensky R, Drug desensitization. Immunol Allergy Clin North 
Am 2004; 24: 425-43.
  6.  Greenberger PA. Drug challenge and desensitization protocols. 
Immunol Allergy Clin North Am 1998; 18: 759-71.
  7.  Kalpaklioglu AF, Baccioglu Kavut A, Erdemoglu AK. 
Desensitization in Interferon-1a Allergy:A Case Report. Int Arch 
Allergy Immunol 2009;149:178-80.
  8.  Taghavi SA, Eshraghian A. Successful interferon desensitization 
in a patient with chronic hepatitis C infection. World J 
Gastroenterol 2009; 33 : 4196-8.
  9.  Castells M. Desensitization for drug allergy. Curr Opin Allergy 
Clin Immunol, 2006; 6 :476-81.
❚ Manuscript received, December 26, 2009; accepted for publication, 
March 31, 2010.
Mehmet Kilic
Fırat Üniversitesi Tıp Fakültesi
Çocuk Salıı ve Hastalıkları AD 
23119 Elazig,Turkey
E-mail: drmkilic@gmail.com
Omalizumab: A Potential New Therapeutic 
Approach for Aspirin-Exacerbated Respiratory 
Disease
I Bobolea,1 P Barranco,1 A Fiandor,1 R Cabañas,1 S Quirce1, 2
1 Allergy Department, Hospital Universitario La Paz, Madrid, 
Spain
2Spanish Network of Centers for Biomedical Research on 
Respiratory Diseases (CibeRes), Spain
Key words:  Omalizumab. Aspirin. Asthma. Nasal polyps. Aspirin-
exacerbated respiratory disease.
Palabras clave: Omalizumab. Aspirina. Asma. Poliposis nasal. 
Enfermedad respiratoria exacerbada por aspirina (EREA).
Patients with aspirin-exacerbated respiratory disease 
(AERD) have chronic rhinosinusitis, recurrent nasal polyposis, 
and persistent asthma. Aspirin desensitization is currently the 
only procedure that has proven successful in stopping the 
natural course of this disease; it prevents regrowth of nasal 
polypoid tissue, achieves better asthma control, and allows the 
patient to take any cyclooxygenase-1 (COX-1) inhibitor [1].
Omalizumab, a humanized recombinant monoclonal antibody 
that blocks the binding of immunoglobulin (Ig) E to its high-
affi nity Fc receptor, is approved for the treatment of moderate 
to severe persistent allergic asthma, but off-label uses have 
also been reported and include food allergy, atopic dermatitis, 
chronic urticaria, mastocytosis, anaphylaxis [2,3], allergic 
bronchopulmonary aspergillosis [4], and more recently refractory 
chronic rhinosinusitis and recurrent nasal polyps [5,6].
We report on an 18-year-old woman, initially diagnosed 
with seasonal rhinoconjunctivitis and asthma due to 
sensitization to grass pollen at the age of 10. In 2008, during 
a follow-up visit at our clinic, she reported the typical onset 
of AERD: a viral cold followed by persistent rhinitis (nasal 
obstruction, progressive hyposmia), difficult-to-control 
asthma, and 3 episodes of severe bronchoconstriction after 
taking ibuprofen 600 mg (twice) and paracetamol 1 g [5].
A methacholine inhalation test was performed and resulted 
positive (0.94 mg/mL of methacholine required to cause a 
20% decrease in forced expiratory volume in the fi rst second 
[FEV
1
] from baseline [PC
20
]). To confi rm the diagnosis of 
AERD, challenge tests with aspirin were programmed but 
could not be performed due to the unstable asthma (despite 
continuous treatment with salmeterol/fl uticasone 50/250 µg 
twice a day, montelukast 10 mg/day, and various cycles of 
systemic corticosteroids) and a FEV
1
 of 65% of predicted. For 
the same reason, it was not possible to try alternative analgesics 
such as COX-2 inhibitors. The patient had to take tramadol 
for the severe headaches she experienced due to her chronic 
rhinosinusitis. Polyps were also diagnosed in 2008, when the 
patient underwent bilateral endoscopic sinus surgery, with 
histological evidence of eosinophilic nasal polyposis.
In June 2009, she was prescribed omalizumab 225 mg 
every 2 weeks (total serum IgE 403 IU/mL, body weight, 48 
kg) to treat persistent severe asthma symptoms.
Within the fi rst month of treatment the patient experienced an 
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improvement in nasal symptoms (congestion and hydrorrhea, and, 
to a lesser extent, hyposmia); 2 months later she had also achieved 
better asthma control (no further need for rescue bronchodilator 
use and no asthma symptoms, leading to the withdrawal of inhaled 
corticosteroids and long-acting ß
2
 agonists, and a signifi cant 
improvement of FEV
1
 up to 90% of predicted). After 16 weeks 
of treatment with omalizumab, the Asthma Control Test score had 
risen from 11 to 25 points, and the asthma-related quality of life 
questionnaire (AQLQ) revealed a score of 6.8. Before starting the 
anti-IgE therapy, she had a severely impaired quality of life, with 
an AQLQ of 3.68 (>1.5 points improvement).
In September 2009, a specifi c bronchial challenge with 
lysine-acetylsalicylate yielded a negative result, and in 
October 2009, an oral challenge with aspirin with a cumulative 
dose of 750 mg was also negative. In the follow-up visit in 
December 2009, a certain degree of hyposmia persisted, despite 
continuous therapy with intranasal corticosteroids, and the 
methacholine test was still positive (PC
20
, 1.84 mg/mL). The 
patient, however, had no asthma symptoms under treatment 
with montelukast and omalizumab only. She had also tolerated 
ibuprofen 600 mg perfectly on several occasions. 
Omalizumab could prove effective in the treatment of 
AERD, as demonstrated by the experience of our patient, who 
not only succeeded in controlling the disease and signifi cantly 
improving her quality of life but is also now capable of 
tolerating aspirin and other COX-1 inhibitors. Further 
studies are required in order to confi rm the effectiveness of 
omalizumab in patients with AERD.
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While cutaneous delayed-type hypersensitivity to topical 
corticosteroids is common, immediate reactions to systemic 
corticosteroids (SC) are rare, with little more than 100 cases 
reported [1-3]. Anaphylaxis and other types of immediate 
reaction to SCs (including urticaria, angioedema, and 
bronchospasm) have been described [4-6]. Hydrocortisone, 
prednisolone, and methylprednisolone are the agents most 
frequently implicated [1,7,8], although hypersensitivity to 
dexamethasone is exceedingly rare. Not only should the 
corticosteroid itself be considered potentially responsible, 
but its specifi c ester, and even the excipients (especially 
carboxymethylcellulose), should be also be taken into 
account [1,9]. 
We retrospectively studied all patients attending the 
drug allergy clinic at Coimbra University Hospitals in 
the last 10 years with an immediate reaction to SCs and 
positive skin test results. Clinical records were consulted 
to obtain information on concomitant medication, timing of 
administration, the reaction, and treatment. Skin prick tests 
(SPT) to parenteral dexamethasone, methylprednisolone, 
hydrocortisone, prednisolone, and latex had been performed 
using an undiluted formulation. 
If the SPT results were negative, intradermal tests 
(IDT) to the same SC were performed in 10-fold increasing 
concentrations (0.002 mg/dL, 0.02 mg/dL, 0.2 mg/dL). Ten 
atopic volunteers (controls) also underwent the same skin 
tests. Specifi c immunoglobulin (Ig) E to methylprednisolone 
(PhadiaTM, Uppsala, Sweden) was determined in the most 
recent reactions (patients 3 and 6).
All patients gave their informed consent to undergo an 
oral challenge test with defl azacort (cumulative dose, 60 mg). 
Dexamethasone was also tested in patients 3 and 5.
Six patients (4 women/2 men, mean [SD] age 48.2 [13.6] 
y) were evaluated. All had been administered the suspect SC 
intravenously. All SPTs to latex were negative. The results are 
summarized in the Table. 
All atopic controls had negative skin test results. 
Specific IgE to methylprednisolone was positive in 
patient 3 (1.6 kUA/L). The challenge test with defl azacort was 
negative in all patients; the challenge test with dexamethasone 
was positive in patient 5. 
Although the most frequent manifestations were 
cutaneous, life-threatening anaphylaxis with hypotension 
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Table. Population and Skin Test Results
  
Patient
 Signs and SC Time From                          Skin Tests
  Symptoms Implicated Reaction to     
Associated
    Skin Tests, y D MP H P Condition 
           
 1 Bronchospasm MP 6 SPT (–) SPT (–) SPT (–) SPT (–) Atopic
     IDT (–) IDT (+) IDT (–) IDT (ND) asthma
      (0.002 mg/dL)
 2 Bronchospasm P 13 SPT (–) SPT (–) SPT (–) SPT (–) AERD
     IDT (ND) IDT (–) IDT (ND) IDT (+)
        (0.002 mg/dL)
 3 1st episode: U, H 2 months SPT (–) SPT (+) SPT (+) SPT (+)
  AE, hypotension   IDT (–) IDT (ND)
 4 1st episode: U 
  2nd episode:    SPT (–) SPT (–)
  bronchospasm, 1st, MP 7 SPT (–) IDT (+) IDT (+) SPT (–) AERD
  anaphylactic 2nd, P  IDT (–) (0.002 mg/dL) (0.2 mg/dL) IDT (ND)
  shock
 5 Anaphylactic    SPT (–)
   MP 13 SPT (–) IDT (+) SPT (–) SPT (–)  Atopic
     IDT (–) (0.02 mg/dL) IDT (–) IDT (–) asthma
 6 Bronchospasm P 3 SPT (–) SPT (–) SPT (–)   SPT (–) Atopic
     IDT (–) IDT (+) IDT (–) IDT (–) asthma
      (0.2 mg/dL)  (0.02 mg/dL) 
Abbreviations: AE, angioedema; AERD, aspirin-exacerbated respiratory disease; D, dexamethasone; H, hydrocortisone; IDT, intradermal test; SC, systemic 
corticosteroid; MP, methylprednisolone; P, prednisolone; SPT, skin prick test; U, urticaria.
occurre in 2 patients. Latex allergy and concomitant drug 
hypersensitivity were ruled out in all participants. In contrast to 
the results of previous reports [1,7], hypersensitivity attributed 
to hydrocortisone was rare, and both methylprednisolone and 
prednisolone were the most commonly implicated SCs in 3 
out of 6 patients each. This may be related to the generalized 
use of these SCs in our hospital.
The literature associates intravenous administration with a 
higher frequency of hypersensitivity reaction [1]. Our results 
support this association, as the drugs were administered 
intravenously in all patients.
Consistent with the fi ndings of other studies, the positive 
skin test results we observed point to an IgE-mediated reaction 
[1,3,8]. 
In our population, 3 out of 6 patients were sensitized to 
2 or more corticosteroids, suggesting cross-reactivity. This 
has also been observed by some authors [2,8,10], but not by 
others [1].
Defl azacort was well tolerated in all cases, thus proving 
to be a viable alternative. Similar results have been reported 
elsewhere [8,10]. The results of skin tests to dexamethasone 
were negative, suggesting that it may be an appropriate 
parenteral option, although the result of challenge testing was 
positive in a patient with a negative skin test result. 
Asthma and renal transplant have been identifi ed as risk 
factors for hypersensitivity to SCs [7]. This is supported in our 
series, as 5 out of 6 patients were asthmatics.
In conclusion, although rare, immediate reactions to SCs 
can be life-threatening. Both IgE-mediated and non–IgE-
mediated mechanisms have to be considered, and skin tests 
can be a valuable ally in the workup. Cross-reactivity can 
occur between different corticosteroids. Finally, defl azacort 
seems to be a viable alternative in patients who experience 
hypersensitivity reaction to SCs.
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The anti-immunoglobulin (Ig) E monoclonal antibody 
omalizumab (Xolair) has been proposed as an innovative 
pharmacological tool in the treatment of poorly controlled 
moderate to severe allergic asthma, which is characterized by 
frequent exacerbations, functional instability, and the need for 
high-dose inhaled corticosteroids, systemic corticosteroids, 
or both [1-3]. 
Management of severe asthma can benefi t from both 
prospective and retrospective monitoring in order to control 
the disease and prevent exacerbations [4,5].
We developed a retrospective monitoring procedure 
based on daily recording of the symptom score and of peak 
expiratory fl ow (PEF), which we routinely apply for as long 
as 10 months (or more, when necessary) in new patients with 
poorly controlled severe asthma. The valuable information 
we collect enables us to confi rm our diagnosis and fi ne-tune 
therapy. The data recorded by patients at follow-up visits on 
monitoring cards are processed in real time by the graphic 
software Sigmaplot 1.0-11.0 (Systat, London, UK), which 
produces high-quality self-explanatory charts that can aid 
management-related rapid decision making through visual 
pattern recognition [5].
We describe our application of these monitoring techniques 
in patients with severe asthma treated with omalizumab (at 
the recommended individually tailored dose). The procedure 
has enabled us to assess the clinical and functional effects 
of omalizumab on asthma before and after treatment in a 
measurable and detailed manner (as in 4 of the 35 cases we 
are currently managing).
As an example of this concept, the Figure depicts the results 
for a 52-year-old male farmer sensitized to Parietaria judaica 
(a perennial allergen in Southern Italy), grass pollen, cypress 
pollen, and cat, and who had been receiving omalizumab from 
March 2007. Comparison of monitoring data collected from 
March 18 to April 16, 2005 (P judaica peak pollen season) with 
those from the same period in 2008 revealed a clear-cut decline 
in symptom scores: a constant score of 3 (maximum, 12) in 2005 
compared with absence of symptoms in 2008. Moreover, PEF 
values stabilized and increased, with a mean (SD) morning value 
of 437 (16) L/min in 2005 vs 498 (12) L/min in 2008, and mean 
evening values of 428 (6) L/min and 493 (6) L/min, in 2005 
and 2008, respectively. Both differences, which were analyzed 
using the t test for unpaired data, were statistically signifi cant 
(P<.0001). The concomitant pharmacological treatment (inhaled 
budesonide 1200 µg tid, nedocromil sodium 4 mg tid, formoterol 
12 µg bid, and montelukast 10 mg daily) remained unchanged 
over the 2 monitoring periods. 
Similar results were obtained in the other cases we 
analyzed. A 65-year-old housewife had a mean morning PEF of 
259 (9) L/min in 2005 compared with 308 (11) L/min in 2008 
(monitoring period, April 1-30; P<.0001). A 49-year-old male 
police offi cer had an average morning PEF of 536 (18) L/min 
in 2005 compared with 591 (15) L/min in 2008 (monitoring 
period, April 15-May 14; P<.0001). 
Analysis of monitoring data for a 67-year-old housewife 
during December 13-January 11 in 2004/2005 and 2008/2009 
revealed a sharp reduction in PEF variability, from 26% 
to 8%, as assessed using the method of minimum morning 
prebronchodilator PEF over 1 week and expressed as a 
percentage of the recent best (Min%Max) [6].
We conclude that retrospective card-based monitoring 
of the symptom score and PEF followed by appropriate 
graphic rendering of the data collected is essential in the 
management of patients with poorly controlled severe asthma. 
This is particularly true when assessing the effi cacy of novel 
therapeutic agents such as omalizumab. The effects of this 
treatment in individual patients can be appraised using visual 
pattern recognition after generation of high-quality charts 
and quantitative determination of changes in PEF values and 
PEF variability.
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Figure. Effect of omalizumab (375 mg every 2 weeks) in a 52-year-old male patient with severe asthma. Graphic rendering (Sigmaplot 1.0) of data from 
retrospective monitoring based on daily recording of symptom scores (triangles; right Y axis; range 0-12a), morning PEF values (circles), and evening PEF 
values (squares) (left Y axis). The data were from exactly the same period of time. A, Spring 2005 (before treatment with omalizumab) and B, Spring 2008 
(during treatment with omalizumab). Predicted PEF values (continuous line) and personal best PEF values (dotted line) can be identifi ed visually. While 
taking omalizumab, the personal best PEF value was reached on April 8, 2008, during the P judaica peak pollen season.
aScores from 0 (absence/normality) to 3 (maximum) were recorded for wheezing, cough, everyday activities, and sleep.
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Self-injectable adrenaline (SIA) devices can save the 
lives of patients who experience anaphylaxis [1]. However, 
their effectiveness depends upon early usage, which in turn 
depends upon early recognition of anaphylaxis by patients (or 
their carers) and familiarity with the device [2]. Training in the 
use of SIA devices has been investigated in pediatric patients 
[3], but not in adults. 
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We carried out a questionnaire-based survey for a 
prospective clinical audit in the allergy clinic of the Heart 
of England NHS Foundation Trust (Birmingham, UK) 
between August and October 2007 in order to assess patients’ 
knowledge of SIA devices and confi dence in their use. All 
patients carrying an SIA device (n=80) and who were attended 
at the allergy clinic during the audit period completed the 
questionnaire. Patients were divided into 3 categories: those 
previously trained in our allergy clinic and attending for 
follow-up (specialist-trained), and newly referred patients who 
were issued SIA devices by nonallergy specialists (such as 
general practitioners, nurses, hospital physicians, pharmacists) 
and either received training (nonspecialist-trained) or did 
not (untrained). Questions were designed to assess training, 
understanding, and confi dence with regard to use of the device. 
Knowledge and confi dence scores (maximum scores of 7 and 
2, respectively) were derived from the responses.
A total of 80 questionnaires were completed: 74 (92.5%) 
were eligible for analysis. Mean (SD) age of the respondents 
was 36.9 (15.17) years and 56 (76%) were female. Thirty (41%) 
of our respondents were specialist-trained, 20 (27%) were 
untrained, and 24 (32%) were trained by nonspecialists. All of 
the untrained patients had their device issued by nonspecialists. 
There was a signifi cant difference in knowledge and confi dence 
scores between specialist-trained and untrained patients: 5.97 
(0.72) vs 5.05 (1.57), P=.007, and 1.5 (0.63) vs 0.75 (0.79), 
P=.001. The differences between knowledge and confi dence 
scores of patients trained by nonspecialists and those who 
were untrained were not signifi cant: 5.75 (0.94) vs 5.05 (1.57), 
P=.075, and 1.13 (0.63) vs 0.75 (0.79), P=0.126. Patient 
confi dence scores between specialist-trained and nonspecialist-
trained patients showed a trend towards signifi cance: 1.5 (0.63) 
vs 1.13 (0.8), P=.06.
The most concerning fi nding in our cross-sectional study 
was that a quarter of patients with SIA devices appeared to 
have received no training whatsoever in their use, with the 
subsequent negative effects on knowledge and confi dence. 
SIA training in our allergy clinic is protocol-driven and 
involves a trainer device and a written management plan. 
Details of training given by nonspecialists were not available, 
although this is likely to be less comprehensive. Indeed, many 
nonspecialists may not be familiar with SIA devices, and this 
could prove detrimental for patients [4].
Anaphylaxis is a serious and potentially fatal condition. To 
issue an SIA device without proper training is dangerous, as 
this can give patients (or carers) a false sense of security, thus 
putting lives at risk in a situation of extreme duress [5]. 
Our study is limited by its small sample size and the lack of 
objective testing (eg, practical demonstration by the patient). 
Nevertheless, we feel that our results highlight pertinent points 
in the management of adult patients with serious allergies. 
Improving outcomes for patients with anaphylaxis at a time 
when the incidence of allergic diseases is growing to epidemic 
proportions requires nonspecialists to be better educated about 
anaphylaxis and SIA device use. Only then can these vulnerable 
patients take full advantage of this truly life saving device.
These data have been presented orally at the EAACI 
conference, Barcelona, Spain, June 2008, and as a poster 
presentation at the BSACI conference, Nottingham, UK, July 
2008.
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